Symbols / PLRZ Stock $13.19 -1.70% Polyrizon Ltd.
PLRZ (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websitePolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Ratings
Current target
$13.19
Low
—
High
—
Mean
—
- Polyrizon (PLRZ) Stock Price, News & Analysis - MarketBeat hu, 18 Jun 2026 07
- Polyrizon patent published for nasal drug-delivery technology - Stock Titan Wed, 17 Jun 2026 12
- PLRZ Stock Price and Chart — NASDAQ:PLRZ - TradingView hu, 04 Dec 2025 08
- $PLRZ stock is up 8% today. Here's what we see in our data. - Quiver Quantitative ue, 21 Apr 2026 07
- We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth - Yahoo Finance Fri, 05 Dec 2025 08
- PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? - Stocktwits hu, 05 Mar 2026 08
- Polyrizon stock surges on human study for allergy blocker - Investing.com Mon, 15 Jun 2026 14
- Polyrizon Ltd. Ordinary Shares (NASDAQ: PLRZ) Stock Price, News & Analysis - Kalkine hu, 18 Jun 2026 20
- Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan Wed, 17 Jun 2026 20
- How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan Mon, 15 Jun 2026 12
- New nasal gel trial to block airborne seasonal allergens in U.S. - Stock Titan Mon, 08 Jun 2026 07
- New nasal drug delivery tech from Polyrizon gets European patent spotlight - Stock Titan Wed, 10 Jun 2026 07
- Polyrizon (NASDAQ: PLRZ) prolongs Arrow Aviation 51% stake talks - Stock Titan Fri, 05 Jun 2026 07
- Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan Mon, 15 Jun 2026 20
- Polyrizon widens U.S. patent bid to cover how nasal drugs stay put - Stock Titan Mon, 04 May 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.79
+344.32%
|
1.30
+105.04%
|
0.64
-29.05%
|
0.90
|
| Research And Development |
|
2.13
+299.44%
|
0.53
+60.84%
|
0.33
-4.32%
|
0.35
|
| Selling General And Administration |
|
3.65
+375.52%
|
0.77
+153.47%
|
0.30
-44.71%
|
0.55
|
| Selling And Marketing Expense |
|
—
|
0.00
|
0.00
-100.00%
|
0.01
|
| General And Administrative Expense |
|
3.65
+375.52%
|
0.77
+153.47%
|
0.30
-43.15%
|
0.53
|
| Salaries And Wages |
|
1.13
+596.30%
|
0.16
-3.57%
|
0.17
-11.58%
|
0.19
|
| Other Gand A |
|
2.52
+316.50%
|
0.61
+348.89%
|
0.14
-60.64%
|
0.34
|
| Total Expenses |
|
5.79
+344.32%
|
1.30
+105.04%
|
0.64
-29.05%
|
0.90
|
| Operating Income |
|
-5.79
-344.32%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| Total Operating Income As Reported |
|
-6.25
-379.95%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| EBITDA |
|
-5.44
-359.71%
|
-1.18
-87.64%
|
-0.63
+29.10%
|
-0.89
|
| Normalized EBITDA |
|
-10.67
-1000.72%
|
-0.97
-8.15%
|
-0.90
+8.76%
|
-0.98
|
| Reconciled Depreciation |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| EBIT |
|
-5.79
-344.32%
|
-1.30
-105.04%
|
-0.64
+29.05%
|
-0.90
|
| Total Unusual Items |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Total Unusual Items Excluding Goodwill |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Special Income Charges |
|
-0.46
|
—
|
—
|
—
|
| Other Special Charges |
|
0.46
|
—
|
—
|
—
|
| Net Income |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Pretax Income |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Non Operating Interest Income Expense |
|
-2.77
-9803.57%
|
-0.03
+87.83%
|
-0.23
-1058.33%
|
0.02
|
| Net Interest Income |
|
-2.77
-9803.57%
|
-0.03
+87.83%
|
-0.23
-1058.33%
|
0.02
|
| Interest Income Non Operating |
|
0.37
|
0.00
|
0.00
|
—
|
| Interest Income |
|
0.37
|
0.00
|
0.00
|
—
|
| Other Income Expense |
|
5.22
+2529.30%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Gain On Sale Of Security |
|
5.69
+2745.12%
|
-0.21
-181.13%
|
0.27
+188.04%
|
0.09
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income From Continuing And Discontinued Operation |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Net Income Continuous Operations |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Normalized Income |
|
-8.56
-543.46%
|
-1.33
-53.76%
|
-0.86
+0.69%
|
-0.87
|
| Net Income Common Stockholders |
|
-3.33
-107.79%
|
-1.60
-139.91%
|
-0.67
+18.71%
|
-0.82
|
| Diluted EPS |
|
—
|
-805.20
-236.52%
|
-239.27
+18.71%
|
-294.35
|
| Basic EPS |
|
—
|
-805.20
-236.52%
|
-239.27
+18.71%
|
-294.35
|
| Basic Average Shares |
|
—
|
0.00
-28.68%
|
0.00
+0.00%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.00
-28.68%
|
0.00
+0.00%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-3.33
-107.79%
|
-1.60
-139.91%
|
-0.67
+18.71%
|
-0.82
|
| Preferred Stock Dividends |
|
—
|
0.06
-13.04%
|
0.07
+56.82%
|
0.04
|
| Total Other Finance Cost |
|
3.14
+11125.00%
|
0.03
-87.83%
|
0.23
+1058.33%
|
-0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
21.44
+286.46%
|
5.55
+892.31%
|
0.56
+2.38%
|
0.55
|
| Current Assets |
|
12.86
+384.73%
|
2.65
+4812.96%
|
0.05
+5.88%
|
0.05
|
| Cash Cash Equivalents And Short Term Investments |
|
12.46
+388.02%
|
2.55
+6129.27%
|
0.04
+13.89%
|
0.04
|
| Cash And Cash Equivalents |
|
1.31
-48.86%
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
|
| Other Short Term Investments |
|
11.16
|
0.00
-100.00%
|
0.04
|
0.00
|
| Other Current Assets |
|
0.40
+300.00%
|
0.10
+661.54%
|
0.01
-13.33%
|
0.01
|
| Total Non Current Assets |
|
8.58
+196.37%
|
2.89
+473.07%
|
0.51
+2.02%
|
0.49
|
| Net PPE |
|
0.01
+20.00%
|
0.01
-16.67%
|
0.01
-25.00%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
2.55
-11.69%
|
2.88
|
0.00
|
—
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.49
+2.92%
|
0.48
|
| Non Current Prepaid Assets |
|
6.02
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
0.44
+69.73%
|
0.26
-65.20%
|
0.75
-48.13%
|
1.45
|
| Current Liabilities |
|
0.44
+69.73%
|
0.26
-48.01%
|
0.50
-58.10%
|
1.20
|
| Payables And Accrued Expenses |
|
0.29
+36.11%
|
0.22
+36.71%
|
0.16
+12.06%
|
0.14
|
| Current Accrued Expenses |
|
0.29
+36.11%
|
0.22
+36.71%
|
0.16
+12.06%
|
0.14
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.15
+231.11%
|
0.04
+15.38%
|
0.04
+5.41%
|
0.04
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Current Debt |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Other Current Borrowings |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Other Current Liabilities |
|
—
|
—
|
0.10
-73.62%
|
0.40
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.25
+0.00%
|
0.25
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
0.25
+0.00%
|
0.25
|
| Stockholders Equity |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Common Stock Equity |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.61
+57420.24%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Ordinary Shares Number |
|
1.61
+57420.24%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
29.39
+183.95%
|
10.35
+193.59%
|
3.53
+74.47%
|
2.02
|
| Retained Earnings |
|
-8.40
-65.83%
|
-5.07
-43.88%
|
-3.52
-20.54%
|
-2.92
|
| Total Equity Gross Minority Interest |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Total Capitalization |
|
20.99
+297.16%
|
5.29
+2867.54%
|
-0.19
+78.78%
|
-0.90
|
| Working Capital |
|
12.42
+419.11%
|
2.39
+633.93%
|
-0.45
+60.94%
|
-1.15
|
| Invested Capital |
|
20.99
+297.16%
|
5.29
+58633.33%
|
0.01
+103.24%
|
-0.28
|
| Total Debt |
|
—
|
—
|
0.20
-67.85%
|
0.62
|
| Net Debt |
|
—
|
—
|
0.20
-66.55%
|
0.59
|
| Net Tangible Assets |
|
18.45
+667.99%
|
2.40
+1357.59%
|
-0.19
+78.78%
|
-0.90
|
| Tangible Book Value |
|
18.45
+667.99%
|
2.40
+1357.59%
|
-0.19
+78.78%
|
-0.90
|
| Other Equity Interest |
|
—
|
—
|
-0.20
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.53
-294.77%
|
-1.15
-113.59%
|
-0.54
+52.56%
|
-1.13
|
| Cash Flow From Continuing Operating Activities |
|
-4.53
-294.77%
|
-1.15
-113.59%
|
-0.54
+52.56%
|
-1.13
|
| Net Income From Continuing Operations |
|
-3.33
-115.86%
|
-1.54
-157.50%
|
-0.60
+22.98%
|
-0.78
|
| Depreciation Amortization Depletion |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Depreciation |
|
—
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Depreciation And Amortization |
|
0.34
+189.83%
|
0.12
+2850.00%
|
0.00
-20.00%
|
0.01
|
| Other Non Cash Items |
|
2.46
+7825.81%
|
0.03
-86.40%
|
0.23
+976.92%
|
-0.03
|
| Stock Based Compensation |
|
1.31
+2468.63%
|
0.05
-49.00%
|
0.10
-23.08%
|
0.13
|
| Operating Gains Losses |
|
-5.14
-2537.91%
|
0.21
+172.01%
|
-0.29
-148.31%
|
-0.12
|
| Gain Loss On Investment Securities |
|
-5.14
-2537.91%
|
0.21
+172.01%
|
-0.29
-148.31%
|
-0.12
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
-100.00%
|
0.01
-52.94%
|
0.02
|
0.00
|
| Change In Working Capital |
|
-0.16
-652.38%
|
-0.02
-400.00%
|
0.01
+102.03%
|
-0.34
|
| Change In Payables And Accrued Expense |
|
0.04
-39.66%
|
0.06
+241.18%
|
0.02
+213.33%
|
-0.01
|
| Change In Accrued Expense |
|
0.04
-39.66%
|
0.06
+241.18%
|
0.02
+213.33%
|
-0.01
|
| Change In Other Working Capital |
|
0.10
+1633.33%
|
0.01
+150.00%
|
-0.01
+96.42%
|
-0.34
|
| Change In Other Current Assets |
|
-0.30
-249.41%
|
-0.09
-4350.00%
|
0.00
-66.67%
|
0.01
|
| Investing Cash Flow |
|
-16.53
-57113.79%
|
0.03
|
0.00
+100.00%
|
-0.00
|
| Cash Flow From Continuing Investing Activities |
|
-16.53
-57113.79%
|
0.03
|
0.00
+100.00%
|
-0.00
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Purchase Of PPE |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Capital Expenditure |
|
-0.01
|
—
|
—
|
-0.00
|
| Net Investment Purchase And Sale |
|
-16.53
-57089.66%
|
0.03
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-16.53
|
0.00
|
0.00
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
0.03
|
0.00
|
0.00
|
| Financing Cash Flow |
|
19.81
+440.19%
|
3.67
+626.34%
|
0.51
-22.07%
|
0.65
|
| Cash Flow From Continuing Financing Activities |
|
19.81
+440.19%
|
3.67
+626.34%
|
0.51
-22.07%
|
0.65
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.01
-102.41%
|
0.25
-61.57%
|
0.65
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.31
+24.50%
|
0.25
-61.57%
|
0.65
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.32
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
0.31
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.32
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.01
|
0.00
|
0.00
|
| Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
0.25
-61.57%
|
0.65
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
0.25
-61.57%
|
0.65
|
| Net Common Stock Issuance |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
| Changes In Cash |
|
-1.25
-148.94%
|
2.55
+8068.75%
|
-0.03
+93.43%
|
-0.49
|
| Beginning Cash Position |
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
-93.12%
|
0.52
|
| End Cash Position |
|
1.31
-48.86%
|
2.55
+63750.00%
|
0.00
-88.89%
|
0.04
|
| Free Cash Flow |
|
-4.54
-295.38%
|
-1.15
-113.59%
|
-0.54
+52.69%
|
-1.14
|
| Common Stock Issuance |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
| Issuance Of Capital Stock |
|
19.81
+439.30%
|
3.67
+1335.16%
|
0.26
|
0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|